To the Editor:
Because the increase in plasma potassium in hemolyzed specimens is linearly related to hemoglobin concentration (1 ) , knowledge of the potassium/ hemoglobin ratio can allow estimation of the magnitude of increase in plasma potassium. Previous estimates of the potassium/hemoglobin ratio have evaluated only a few apparently healthy volunteers (2) (3) (4) . Interindividual differences, particularly in diseased populations, could produce variability in correction factor determination. This letter describes the interindividual variability in the potassium/hemoglobin ratio for in vitro hemolysis in 100 hospitalized patients.
Erythrocyte hemolysates were prepared by the procedure of Meites (5 ) . Briefly, the erythrocytes from lithiumheparin-blood samples from 100 medical and surgical inpatients were separated by centrifugation at 2500g within 1 h of collection, washed three times with isotonic saline, and then lysed by the addition of an equal volume of distilled water. After freezing overnight and thawing, the hemolysates were centrifuged at 2500g for 30 min to remove the stroma.
For each of the 100 patient hemolysate samples, 100 L of hemolysate was added to 2 mL of a common pooled serum to produce a severely hemolyzed sample. This was diluted in the common pooled serum to form a series of nine equispaced, linearly related samples. Each series of the diluted samples was analyzed in duplicate (same batch) for potassium (reported to two decimal places with an indirect ion-selective electrode) and hemolysis index (multiwavelength spectrophotometry with saline as the reagent) on a Roche Diagnostics 917 clinical chemistry analyzer. Pearson correlation coefficient calculation and Deming model linear regression analysis by Analyse-It add-on software were performed for each dilution series, and the slope of the potassium/ hemoglobin relationship was noted.
The range of hemoglobin concentrations tested was 50 -6000 mg/L. Within-batch CVs were as follows: potassium, 0.4%; hemoglobin, 2%. The range of correlation coefficients for the 100 dilution series was 0.99 -1.00, confirming the linear relationship between potassium and hemoglobin. The median potassium/ hemoglobin (mmol/g) ratio was 28.0, with a mean of 28.4, and the 95% population limits were 21.0 and 34.5 ( Fig. 1) . Although the population range included published individual experimental values (1 ), the median and mean were lower than other individual estimates (1-4, 6, 7 ) . There was also a substantial difference between the 2.5 and 97.5 percentiles, which would create difficulty in the choice of ratio when correcting potassium values for hemolysis in a given case. Thus, because of the variability in the potassium/hemoglobin ratio demonstrated here, the correction of potassium increase in specimens exhibiting in vitro hemolysis is not advocated.
Increased Homocysteine in Liver
Cirrhosis: A Result of Renal Impairment?
To the Editor:
In their recent publication, Ferré et al.
(1 ) investigated homocysteine concentrations in 76 patients with liver cirrhosis. The majority of these patients suffered from alcoholic liver disease (63%). The authors described significantly increased homocysteine in nonabstaining alcoholic patients with cirrhosis. Furthermore, the homocysteine concentrations were inversely correlated with the severity of the liver disease (Child-Pugh score) and with the folate concentra- Letters tions in these patients. The authors proposed that the homocysteine concentration was influenced by alcohol intake and by the degree of liver impairment. The authors conclude that nonnutritional factors may affect homocysteine concentrations.
Hyperhomocysteinemia also occurs in patients with decreased renal function, but the investigators provided no information about the renal function of these patients. Renal function is considerably reduced in patients with compensated cirrhosis (2 ) . An inverse relationship between the glomerular filtration rate (GFR) and plasma homocysteine has been noted, and declining renal function is associated with higher plasma homocysteine concentrations (3 ) .
We studied 23 patients with liver cirrhosis (median age, 54 years; range, 20 -68 years; 16 males, 7 females). The etiology of cirrhosis was alcoholic liver disease in 18 (78%), and ascites was present in 21 (91% Proposed mechanisms of hyperhomocysteinemia include reduced renal elimination of homocysteine and impaired vitamin-dependent liver metabolism (4 ) . Urinary homocysteine excretion in humans is minimal. However, loss of putative renal homocysteine extraction in chronic renal failure has been hypothesized because significant homocysteine uptake has been demonstrated in the healthy rat kidney. In fasting humans with normal renal function, however, no significant net renal uptake of homocysteine occurs (5 ) .
To date, the pathways of methionine-homocysteine metabolism are not fully understood, and further research is needed. Baseline data on renal function are mandatory to allow interpretation of hyperhomocysteinemia, which correlates with both renal and liver impairment. 
Rainer

Drs. Ferré, Camps, and Joven respond:
To the Editor: We read with interest the letter by Woitas et al. commenting our report (1 ) . We agree with these authors in that renal function must be considered in the interpretation of hyperhomocysteinemia. We reported (2 ) that renal failure and tubular damage are main predictors of hyperhomocysteinemia in patients with the nephrotic syndrome. However, we do not think that renal impairment is a major determinant of plasma homocysteine alterations in the cirrhotic patients described in our study (1 ) .
We measured plasma creatinine concentrations in 59 of our patients. Most of them (n ϭ 50) were classified as Child-Pugh A and had well-preserved renal function with a mean (Ϯ SD) plasma creatinine of 80 (Ϯ 4) mol/L and a relatively high mean plasma homocysteine concentration of 12.7 (Ϯ 3.2) mol/L. Seven patients were classified as Child-Pugh B and presented with a similar plasma creatinine (82 Ϯ 9 mol/L) and, interestingly, lower homocysteine (9.3 Ϯ 0.8 mol/L). Only two patients were classified as ChildPugh C, having impaired renal function (plasma creatinine, 159 Ϯ 94 mol/L) and a relatively low plasma homocysteine (9.1 Ϯ 3.1 mol/L).
Although our results may appear to be different from those of Woitas et al., we do not think they are. We Clinical Chemistry 48, No. 5, 2002 think that our two cirrhotic populations are not comparable because the degree of severity of the disease was very different: most of their patients were decompensated (21 of 23 had ascites), and their Child-Pugh score was considerably higher than that of our patients (median score, 9 vs 6).
In our opinion, the two studies are complementary and may reflect a quite complex picture in which increases in plasma homocysteine concentrations (secondary to alcohol intake) are observed at the earliest stages of the disease, followed by normalization at intermediate stages (secondary perhaps to the loss of functional liver mass) and further increases (related to renal impairment) in the more severe groups of patients. (2 ) . Increased MMP3 expression was observed in breast cancer with its presence in the stroma (3 ). MMP3 can degrade many extracellular matrix proteins and cell-surface molecules, including collagens, tumor necrosis factor-␣ precursor, and Ecadherin (2 ), and activate other MMPs (4 ). Furthermore, it can induce molecular events leading to epithelial-mesenchymal conversion and a premalignant phenotype in mouse mammary epithelial cells (5 ) and also lead to spontaneous premalignant lesions in mammary glands of transgenic mice (6 ) .
Natàlia Ferré
A common Ϫ1171 (5A/6A) polymorphism in the promoter region of MMP3 was reported to be functional, with the 6A allele corresponding to a lower reporter gene expression in transient transfection experiments (7 ). Individuals homozygous for 6A had a more rapid progression of coronary atherosclerosis (7 ) . Recently, Biondi et al. (8 ) reported an increased risk of cancer (especially breast cancer) in homo-and heterozygous carriers of the 5A allele in a study of 164 controls and 160 cancer patients, which included 43 breast, 63 colorectal, 25 ovarian, and 29 pulmonary cancer patients from Italy.
To confirm whether the 5A allele confers any risk of breast cancer, we genotyped germline DNA of 182 controls and 246 breast cancer patients from two European populations using PCR single-strand conformation polymorphism analysis (Table 1 ). The ascertainment of patients and controls was as described (9 ) . Direct nucleotide sequencing of three distinct singlestrand conformation polymorphism patterns unambiguously confirmed genotypes. We found no difference in allele or genotype frequencies between controls and breast cancer patients ( 2 ϭ 0.3; 2 df; P Ͼ0.05; Table 1 ). Furthermore, the proportion of carriers with the 5A allele (heterozygotes and homozygotes) was not different between breast cancer patients and controls (Table 1) , thus not confirming the results of Biondi et al. (8 ) and not supporting any modifying influence of the 5A allele on breast cancer susceptibility. Using the HWE utility of the LINKAGE program package (http:// linkage.rockefeller.edu/soft/list.html), we also tested whether the distribution of genotypes deviated significantly from the Hardy-Weinberg equilibrium in each analyzed group, but no bias was found (P Ͼ0.05).
A clue to the discrepancy between our findings and the Italian data may lie in interpreting the results of Biondi et al. (8 ) . A reanalysis of these data indicates that neither allele frequencies ( 2 ϭ 0.9; P Ͼ0.05) nor genotype frequencies ( 2 ϭ 4.9; P Ͼ0.05) were statistically different be- tween the cancer patients and controls. The frequency of the 5A allele in the Italian patients with breast cancer (60.5%) was higher than the frequency of this allele in our cases (Table 1) , but this may be attributable to small numbers of cases with mammary tumors (n ϭ 43) in the Italian study. Clearly, although MMP3 was suggested to play a role in tumor initiation in studies on transgenic mice (5 ) and mouse mammary tumor cell lines (6 ) , more data will be needed to support the previous conclusion (8 ) .
Application of the Bland-Altman Plot for Interpretation of MethodComparison Studies: A Critical Investigation of Its Practice
To the Editor: Current guidelines for the combined graphical/statistical interpretation of method-comparison studies (1 ) include a scatter plot combined with correlation and regression analysis (2 ) and/or a difference plot combined with calculation of the 2s limits of the differences between the methods (the so-called 95% limits of agreement) (3, 4 ) . The former approach has a long tradition in clinical chemistry, and its advantages and pitfalls are well known (5 ). The latter approach, however, which was deemed "simple both to do and to interpret" and was propagated as a substitute for regression analysis (4, 5 ) , became available only in recent years and has increased in popularity. The general features of the Bland-Altman plot have been well described (4 ) (see also Fig. 1A ). The x axis shows the mean of the results of the two methods ([A ϩ B]/2), whereas the y axis represents the absolute difference between the two methods ([B Ϫ A]). When the standard deviation increases with concentration, Bland and Altman recommend a logarithmic y scale, whereas others propose a percent y scale (6 ). Although generally there is not much difference in effect between using percentages and using a log transformation of the data, we prefer the percent plot (except when data extend over several orders of magnitude) because numbers can be read directly from the plot without the need for back-transformation. Additionally, the plot includes the line for the mean difference and the experimentally observed 2s limits of the differences between the methods. Often forgotten, the Bland-Altman approach consists of a comparison of the 2s limits with a clinically acceptable difference between the two methods.
We reviewed difference plots published in this journal and discuss here the key aspects associated with their use. We screened all articles in this journal, starting from the first issue of 1995 up to May 2001. We observed increasing use of the Bland-Altman plot over the years, from 8% in 1995 to 14% in 1996, and 31-36% in more recent years. In addition to the Bland-Altman method, method comparisons were performed using correlation and regression analysis and the concordance plot. In total, we found 96 uses of difference plots [listed in the Data Supplement that accompanies the online version of this letter at Clinical Chemistry Online (clinchem.org/ content/vol48/issue5)]. Most authors also used correlation and regression analysis, suggesting that difference plots are viewed as complementary to, rather than substitutes for, regression analysis. Among 96 references (in total, 98 plots) with Bland-Altman plots, 75 used the absolute difference plot, 20 applied a percent y-scale version, and 3 a logarithmic version of the plot. In total, 50 presented the results in an additional scatter plot.
The following general problems were observed. In 13 cases, the x axis was constructed using only the values of the comparison method (see Data Supplement, Addendum 2, for listing). By doing so, however, the plot may falsely show a concentrationdependent difference even when there is none (7 ) . The 2s limits were presented in only 67 cases, and most importantly, only 2 authors compared the 2s limits with a clinically acceptable difference between the two methods. The 2s limits were more generally used in absolute (59) and logarithmic (3) difference plots, but rarely in percent (5) This apparently results from the fact that the "Instructions for Authors" deprecate the use of regression analysis, which traditionally is accompanied by a scatter plot. Bland and Altman (4 ) show method comparisons that cover a small concentration range and data sets without proportional differences between the methods. In this situation, a constant standard deviation may be assumed, and parallel 2s limits and a mean bias are justified (Fig.  1A) . However, this case is rather unusual in clinical chemistry. In the 75 examined references with absolute difference plots (showing 103 figures ), we found, by eye, 57 data sets with a standard deviation increasing with concentration and/or with a proportional difference (see Fig. 1B ). In these cases, Bland and Altman recommend the use of a log transformation of the data points. Neither a mean bias (in Fig. 1B suggested by the horizontal line at 0.6 mmol/L) nor constant and parallel 2s limits are justified. Rather, the 2s limits should be "V-shaped" around the regression line of the differences (8, 9 ) (see Fig.  1C ). Alternatively, to use parallel 2s limits, a percent difference plot can be used (Fig. 1D) . Overall, we found that 87% of plots had technical flaws, similar to data reported by Mantha et al. (10 ) , who made an analogous survey in the field of anesthesia. Most striking, in both surveys, interpretation of the data by comparison of the actually observed limits of agreement with a priori ones was missing in Ͼ90% of the cases. In summary, difference plots are useful for the presentation and interpretation of method-comparison studies, but most authors in this journal use them as supplements to regression analysis and the scatter plot, a practice that is also recommended by the NCCLS (1 ). Unfortunately, many authors uncritically apply the classical absolute difference plot in method-comparison studies that cover a wider concentration range, where they would better use a percent (or log) difference plot. Last but not least, the main objective of the Bland-Altman approach, namely, comparison of the experimentally observed deviations with a preset clinical acceptance limit, is seldom followed despite recommendations for doing so that were given earlier in this journal (11 ) .
To emphasize, the key aspects of the appropriate construction and use of the Bland-Altman plot are the following. The x axis should be constructed by the mean of the methods and the y axis in a way that is most sensible to the concentration range of the x data (absolute: small range; percentage: medium range; log-scale: large range). The 95% limits of agreement should reflect the actually observed nature of the differences (whether or not there is a relationship between difference and magnitude) (9 ) . Most important, interpretation of the data should be done by comparison of the observed limits of agreement with a priori ones.
As a final note, we want to remark that in this journal, already in 1981, a similar plot (with the y axis constructed as a ratio) was proposed for the evaluation of method-comparison data (12 ) . Strange to say, this report has been overlooked. This work was supported by the Research Fund of the University Ghent (Grant BOF 011109000). 
Katy
In the following commentary, Drs. Altman and Bland elaborate on the issues raised in the above letter:
Commentary on Quantifying Agreement between Two Methods of Measurement
Our interest in the analysis of method comparison studies stemmed from discussions about consulting problems we were independently working on in the late 1970s. Examination of published papers showed that, at that time, most authors were using the Pearson correlation coefficient. It was obvious to us that this method did not assess agreement, but association, and that a high correlation was no guarantee of good agreement.
We felt that a comparison of two methods of measurement, such as different assays, should attempt to quantify the differences and that P values were largely irrelevant. The question is not whether the two methods agree, but how closely they agree. Our statistical approach was based on investigation of the distribution of the between-method differences. We suggested summarizing the data by the mean and 95% range of the differences, which we called the 95% limits of agreement. The graph, which many think is the whole of our method, was intended as a visual check that the approach was reasonable and that the data were "well-behaved". Thus the graph shows whether the variability of differences between methods is roughly constant across the range of measurement, but the key element of the approach is to examine and summarize the individual differences between the two methods. Indeed, in our original paper we included histograms of these differences. This distribution should be approximately normal, and (apart from occasional outliers) this is usually what we see.
Our first two papers outlined the basic ideas (1, 2 ) , but a recent report contained the fullest exposition of our method, including various extensions to deal with replicated observations and complex relationships between the between-method difference and the magnitude of the measurement (3 ).
Our original work related to clinical rather than laboratory measurements, but it was soon obvious that, broadly speaking, the same issues arose. Concerns about the use of the Pearson correlation coefficient had been expressed in this Journal as long ago as 1973 (4 ), but the method remained widespread for decades (and it still is in the wider medical literature).
The idea of plotting difference vs mean was not new (5 ), but as far as we knew its use had not been proposed in this context. The same type of plot was suggested as a general purpose approach for method comparison studies at around the same time (6 ), although without any suggestion for quantifying the differences between the methods.
A particular issue that we were aware of from the start is that there are some measurements where the between-method (and withinmethod) variability increases as the measurement increases. We found that the SD of the differences tended to be proportional to the size of the measurement, so that log transformation of the original data led to Clinical Chemistry 48, No. 5, 2002 differences in the log scale that were unrelated to the size of the measurement. This situation arises commonly in clinical chemistry. Our original suggestion was to take logarithms of the original data, the natural approach to a mathematician, but working with the ratio of the two methods (3 ) or the percentage difference (7 ) gives almost the same answers and is more transparent to the laboratory scientist.
Another important issue is that the full comparison of the performance of two methods of measurement ought to include repeated measurements. Such repeat data can be used to compare observers or instruments, or simply to assess random error.
The very wide uptake of the limits of agreement approach has naturally been very pleasing. We have been aware, however, that sometimes the method has not been adopted with full understanding. For example, we have seen it suggested that two methods agree well because most of the observations lie within the 95% limits of agreement. The limits are calculated so that this will always be the case. We welcome the review by Dewitte et al. of method comparison studies in this Journal. They found that some authors are not making the best use of the method. The most common problem was that investigators plotted the differences against the values obtained by one method. We note, however, that this error will matter much less in situations where there is relatively little measurement error vs between-individual variation, as is the case for many analyses presented in this Journal.
Other aspects of methodology that could benefit from more thought include sample size and how the participants are selected.
Lastly we want to comment on interpretation. We agree that the acceptability of a new method should be based on clinical rather than statistical criteria (2 ) and that the criteria should ideally be prespecified. Relating the criterion of acceptability to goals for analytical quality may be a helpful suggestion (8 ) .
